Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.

Samant TS, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A, Mueller-Zsigmondy M, Umehara K, Huth F, Miller M, Germa C, Elmeliegy M.

Clin Pharmacol Ther. 2017 Nov 14. doi: 10.1002/cpt.940. [Epub ahead of print]

PMID:
29134635
2.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA.

Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.

3.

Food consumption and activity levels increase in rats following intranasal Hypocretin-1.

Dhuria SV, Fine JM, Bingham D, Svitak AL, Burns RB, Baillargeon AM, Panter SS, Kazi AN, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2016 Aug 3;627:155-9. doi: 10.1016/j.neulet.2016.05.053. Epub 2016 Jun 2.

PMID:
27264485
4.

Inflammatory myofibroblastic tumour of sigmoid mesocolon in a child.

Dhuria S, Kwatra KS, Ghosh DN.

ANZ J Surg. 2016 May 19. doi: 10.1111/ans.13625. [Epub ahead of print] No abstract available.

PMID:
27193458
5.

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.

Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB.

J Clin Oncol. 2014 Oct 1;32(28):3103-10. doi: 10.1200/JCO.2013.52.3993. Epub 2014 Aug 11.

PMID:
25113756
6.

Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects.

Dhuria S, Einolf H, Mangold J, Sen S, Gu H, Wang L, Cameron S.

J Clin Pharmacol. 2013 Jun;53(6):642-53. doi: 10.1002/jcph.79. Epub 2013 Apr 15.

PMID:
23585187
7.

Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharm Sci. 2010 Apr;99(4):1654-73. doi: 10.1002/jps.21924. Review.

PMID:
19877171
8.

Antileishmanial effect of cisplatin against murine visceral leishmaniasis.

Kaur S, Sachdeva H, Dhuria S, Sharma M, Kaur T.

Parasitol Int. 2010 Mar;59(1):62-9. doi: 10.1016/j.parint.2009.10.006. Epub 2009 Oct 21.

PMID:
19853668
9.

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharm Sci. 2009 Jul;98(7):2501-15. doi: 10.1002/jps.21604.

PMID:
19025760
10.

Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharmacol Exp Ther. 2009 Jan;328(1):312-20. doi: 10.1124/jpet.108.145565. Epub 2008 Oct 22.

Supplemental Content

Loading ...
Support Center